J&J's boost in Doxil supply benefits study of Endocyte/Merck drug

Johnson & Johnson ($JNJ) has come through with more of its cancer drug Doxil to fill orders from biotechs that need the drug for their clinical trials, after months of rationing the drug because of a key supplier's manufacturing problems. As The Wall Street Journal reported, Endocyte ($ECYT) is grabbing some of the extra Doxil for a late-stage trial of its drug partnered with Merck ($MRK) for ovarian cancer. Endocyte is testing a combination of its experimental EC145 in combination with Doxil versus Doxil alone. Article